MedTrace Logo

A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)

NCT02616185 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 91

Last updated 2023-11-02

Study results available
· View outcomes & findings →

Summary

The study will evaluate the safety, pharmacokinetics and pharmacodynamics of increasing doses of a vaccine-based immunotherapy regimen for patients with prostate cancer.

Conditions

  • Prostatic Neoplasms

Interventions

BIOLOGICAL

PF-06755992

PF-06755992 will be administered on Day 1 of Cycles 1 and 2.

BIOLOGICAL

PF-06755990

PF-06755990 will be administered using a device on Day 29, 57 and 85 of each cycle.

DEVICE

TDS-IM Electroporation Device

TDS-IM electroporation device and associated supplies will be used for PF-06755990 administration

BIOLOGICAL

Tremelimumab

PF-06753388 will be administered every 28 days.

BIOLOGICAL

PF-06801591

PF-06801591 will be administered every 28 days.

BIOLOGICAL

PF-06753512

Combination of adenovirus (AdC68) + plasmid DNA (pDNA) + tremelimumab

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-30
Primary Completion
2021-02-23
Completion
2021-02-23

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02616185 on ClinicalTrials.gov